Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases

Expert Review of Medical Devices

Volumn 9, Issue 1, 2012, Pages 71-83

  Lapchak, Paul A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

acute ischemic stroke; Alzheimer's disease; LLLT; mitochondria; neuroprotection; NILT; Parkinson's disease; photobiomodulation; photobiostimulation; TLT; traumatic brain injury

Indexed keywords

ACUTE ISCHEMIC STROKE; ALZHEIMER'S DISEASE; LLLT; NEUROPROTECTION; NILT; PARKINSON'S DISEASE; PHOTOBIOMODULATION; PHOTOBIOSTIMULATION; TLT; TRAUMATIC BRAIN INJURIES;

BRAIN; DISEASE CONTROL; INFRARED DEVICES; INFRARED LASERS; LASER SURGERY; LASER TISSUE INTERACTION; MITOCHONDRIA; MOLECULAR BIOLOGY;

NEURODEGENERATIVE DISEASES;

ALTEPLASE; AMYLOID BETA PROTEIN; CYTOCHROME C OXIDASE; INTERLEUKIN 1BETA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; AMNESIA; ANGIOGENESIS; ARTIFICIAL EMBOLISM; ATTENTION; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL ENERGY; CELL FUNCTION; CELL RESPIRATION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE SEVERITY; ENERGY YIELD; ENZYME ACTIVATION; ENZYME ACTIVITY; EXECUTIVE FUNCTION; HUMAN; LIFESPAN; LIGHT EMITTING DIODE; LOW LEVEL LASER THERAPY; MITOCHONDRION; MORTALITY; MOTOR PERFORMANCE; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NONHUMAN; NONINVASIVE TRANSCRANIAL NEAR INFRARED LASER THERAPY; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PLASTICITY; PLEIOTROPY; PULSE WAVE; RADIATION DOSE; RADIATION SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RIGIDITY; STROKE PATIENT; THERAPY; TRAUMATIC BRAIN INJURY; TREATMENT CONTRAINDICATION; VERBAL MEMORY;

ACUTE DISEASE; ANIMALS; CHRONIC DISEASE; HUMANS; LASER THERAPY; NEURODEGENERATIVE DISEASES; RECOVERY OF FUNCTION;

EID: 83155160734     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/erd.11.64     Document Type: Review

References (100)

1. Lapchak PA. Taking a light approach to treating acute ischemic stroke patients: transcranial near-infrared laser therapy translational science. Ann. Med. 42(8), 576-586 (2010).
2. Anders JJ, Borke RC, Woolery SK, Van de Merwe WP. Low power laser irradiation alters the rate of regeneration of the rat facial nerve. Lasers Surg. Med. 13(1), 72-82 (1993).
3. Castro-e-Silva O Jr, Zucoloto S, Marcassa LG et al. Spectral response for laser enhancement in hepatic regeneration for hepatectomized rats. Lasers Surg. Med. 32(1), 50-53 (2003).
4. Mochizuki-Oda N, Kataoka Y, Cui Y, Yamada H, Heya M, Awazu K. Effects of near-infra-red laser irradiation on adenosine triphosphate and adenosine diphosphate contents of rat brain tissue. Neurosci. Lett. 323(3), 207-210 (2002).
5. Desmet KD, Paz DA, Corry JJ et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed. Laser Surg. 24(2), 121-128 (2006).
6. Nissan M, Rochkind S, Razon N, Bartal A. HeNe laser irradiation delivered transcutaneously: its effect on the sciatic nerve of rats. Lasers Surg. Med. 6(5), 435-438 (1986).
7. Byrnes KR, Waynant RW, Ilev IK et al. Light promotes regeneration and functional recovery and alters the immune response after spinal cord injury. Lasers Surg. Med. 36(3), 171-185 (2005).
8. Oron U, Yaakobi T, Oron A et al. Low-energy laser irradiation reduces formation of scar tissue after myocardial infarction in rats and dogs. Circulation 103(2), 296-301 (2001).
9. Ad N, Oron U. Impact of low level laser irradiation on infarct size in the rat following myocardial infarction. Int. J. Cardiol. 80(2-3), 109-116 (2001).
10. De Taboada L, Ilic S, Leichliter-Martha S, Oron U, Oron A, Streeter J. Transcranial application of low-energy laser irradiation improves neurological deficits in rats following acute stroke. Lasers Surg. Med. 38(1), 70-73 (2006).
11. Ilic S, Leichliter S, Streeter J, Oron A, DeTaboada L, Oron U. Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain. Photomed. Laser Surg. 24(4), 458-466 (2006).
12. Lampl Y, Zivin JA, Fisher M et al. Infrared laser therapy for ischemic stroke: a new treatment strategy: results of the NeuroThera Effectiveness and Safety Trial-1 (NEST-1). Stroke 38(6), 1843-1849 (2007).
13. Lapchak PA, Araujo DM. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin. Emerg. Drugs 12(1), 97-112 (2007).
14. Naeser MA, Saltmarche A, Krengel MH, Hamblin MR, Knight JA. Improved cognitive function after transcranial, light-emitting diode treatments in chronic, traumatic brain injury: two case reports. Photomed. Laser Surg. 29(5), 351-358 (2011).
15. Eells JT. Therapeutic photobiomodulation for methanol-induced retinal toxicity. Proc. Natl Acad. Sci. USA 100, 3439 (2003).
16. Karu T. Mitochondrial mechanisms of photobiomodulation in context of new data about multiple roles of ATP. Photomed. Laser Surg. 28(2), 159-160 (2010).
17. Drochioiu G. Laser-induced ATP formation: mechanism and consequences. Photomed. Laser Surg. 28(4), 573-574 (2010).
18. Karu TI, Pyatibrat LV, Kolyakov SF, Afanasyeva NI. Absorption measurements of a cell monolayer relevant to phototherapy: reduction of cytochrome c oxidase under near IR radiation. J. Photochem. Photobiol. B Biol. 81(2), 98-106 (2005).
19. Lapchak PA, De Taboada L. Transcranial near infrared laser treatment (NILT) increases cortical adenosine-5- triphosphate (ATP) content following embolic strokes in rabbits. Brain Res. 1306, 100-105 (2010).
20. Huang YY, Chen AC, Carroll JD, Hamblin MR. Biphasic dose response in low level light therapy. Dose Response 7(4), 358-383 (2009).
21. Liang HL, Whelan HT, Eells JT, Wong-Riley MT. Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. Neuroscience 153(4), 963-974 (2008).
22. Oron A, Oron U, Chen J et al. Low-level laser therapy applied transcranially to rats after induction of stroke significantly reduces long-term neurological deficits. Stroke 37(10), 2620-2624 (2006).
23. Leung MC, Lo SC, Siu FK, So KF. Treatment of experimentally induced transient cerebral ischemia with low energy laser inhibits nitric oxide synthase activity and up-regulates the expression of transforming growth factor-beta 1. Lasers Surg. Med. 31(4), 283-288 (2002).
24. Uozumi Y, Nawashiro H, Sato S, Kawauchi S, Shima K, Kikuchi M. Targeted increase in cerebral blood flow by transcranial near-infrared laser irradiation. Lasers Surg. Med. 42(6), 566-576 (2010).
25. Lapchak PA, Wei J, Zivin JA. Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke 35(8), 1985-1988 (2004).
26. De Taboada L, Yu J, El-Amouri S et al. Transcranial laser therapy attenuates amyloid-b peptide neuropathology in amyloid-b protein precursor transgenic mice. J. Alzheimers Dis. 23(3), 521-535 (2011).
27. Lapchak PA. Emerging therapies: pleiotropic multi-target drugs to treat stroke victims. Transl. Stroke Res.2(2), 129-135 (2011).
28. Lyden P, Lu M, Jackson C et al. underlying structure of the national institutes of health stroke scale: results of a factor analysis. Stroke 30, 2347 (1999).
29. Payabvash S, Kamalian S, Fung S et al. Predicting language improvement in acute stroke patients presenting with aphasia: a multivariate logistic model using location-weighted atlas-based analysis of admission CT perfusion scans. AJNR Am. J. Neuroradiol. 31(9), 1661-1668 (2010).
30. Kasner SE. Clinical interpretation and use of stroke scales. Lancet Neurol. 5(7), 603-612 (2006).
31. Singer OC, Dvorak F, du Mesnil de Rochemont R, Lanfermann H, Sitzer M, Neumann-Haefelin T. A simple 3-item stroke scale: comparison with the National Institutes of Health Stroke Scale and prediction of middle cerebral artery occlusion. Stroke 36(4), 773-776 (2005).
32. Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl. Stroke Res. 1(2), 96-107 (2010).
33. Turner R, Jickling G, Sharp F. Are underlying assumptions of current animal models of human stroke correct: from STAIRS to high hurdles? Transl. Stroke Res. 2(2), 138-143 (2011).
34. Lapchak PA, Salgado KF, Chao CH, Zivin JA. Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes. Neuroscience 148(4), 907-914 (2007).
35. Lapchak PA. A clinically relevant rabbit embolic stroke model for acute ischemic stroke therapy development: mechanisms and targets. In: Translational Stroke Research: From Target Selection to Clinical Trials. Lapchak PA, Zhang JH (Eds). Springer, New York, NY, USA (2012).
36. Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359(13), 1317-1329 (2008).
37. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333(24), 1581-1587 (1995).
38. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator. A science advisory from the American Heart Association/American Stroke Association. Stroke 40(8), 2945-2948 (2009).
39. Lapchak PA, Zivin J. Transcranial near-infrared laser therapy improves behavior and differentially regulates the expression of rapid response elements in rabbits following embolic strokes. Stroke 49, P268 (2009).
40. Helm GA, Alden TD, Sheehan JP, Kallmes D. Bone morphogenetic proteins and bone morphogenetic protein gene therapy in neurological surgery: a review. Neurosurgery 46(5), 1213-1222 (2000).
41. Marini AM, Jiang X, Wu X et al. Preconditioning and neurotrophins: a model for brain adaptation to seizures, ischemia and other stressful stimuli. Amino Acids 32(3), 299-304 (2007).
42. Reichardt LF. Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361(1473), 1545-1564 (2006).
43. Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr. Opin. Neurobiol. 11(3), 272-280 (2001).
44. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu. Rev. Neurosci. 24, 677-736 (2001).
45. Lapchak PA, Beck KD, Araujo DM, Irwin I, Langston JW, Hefti F. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection. Neuroscience 53(3), 639-650 (1993).
46. Tabruyn SP, Griffioen AW. Molecular pathways of angiogenesis inhibition. Biochem. Biophys. Res. Commun. 355(1), 1-5 (2007).
47. Zivin JA, Albers GW, Bornstein N et al. Effectiveness and safety of transcranial laser therapy for acute ischemic stroke. Stroke 40(4), 1359-1364 (2009).
48. Lyden P, Lu M, Jackson C et al. Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke 30(11), 2347-2354 (1999).
49. Bluhmki E, Chamorro A, Davalos A et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 8(12), 1095-1102 (2009).
50. Saver JL, Gornbein J, Grotta J et al. Number needed to treat to benefit and to harm for intravenous tissue plasminogen activator therapy in the 3- to 4.5-hour window. Joint outcome table analysis of the ECASS 3 trial. Stroke 40, 2433-2437 (2009).
51. Saver JL, Gornbein J. Treatment effects for which shift or binary analyses are advantageous in acute stroke trials. Neurology 72(15), 1310-1315 (2009).
52. Lynnerup N, Astrup JG, Sejrsen B. Thickness of the human cranial diploe in relation to age, sex and general body build. Head Face Med. 1, 13 (2005).
53. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic resonance images. Proc. Natl Acad. Sci. USA 97(20), 11050-11055 (2000).
54. Wan S, Parrish JA, Anderson RR, Madden M. Transmittance of nonionizing radiation in human tissues. Photochem. Photobiol. 34(6), 679-681 (1981).
55. Oron A, Oron U, Streeter J, Alexandrovich A, Trembovler V, Shohami E. Low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits. J. Neurotrauma 24(4), 651-656. (2007).
56. Yatsiv I, Morganti-Kossmann MC, Perez D et al. Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J. Cereb. Blood Flow Metab. 22(8), 971-978 (2002).
57. Chen Y, Constantini S, Trembovler V, Weinstock M, Shohami E. An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. J. Neurotrauma 13(10), 557-568 (1996).
58. Wu Q, Huang Y-Y, Dhital S et al. Low level laser therapy for traumatic brain injury. SPIE Proceedings 7552, 755206-8 (2010).
59. Ashman TA, Gordon WA, Cantor JB, Hibbard MR. Neurobehavioral consequences of traumatic brain injury. Mt Sinai J. Med. 73(7), 999-1005 (2006).
60. Helmy A, Vizcaychipi M, Gupta AK. Traumatic brain injury: intensive care management. Br. J. Anaesth. 99(1), 32-42 (2007).
61. Kiraly M, Kiraly SJ. Traumatic brain injury and delayed sequelae: a review - traumatic brain injury and mild traumatic brain injury (concussion) are precursors to later-onset brain disorders, including early-onset dementia. Sci. World J. 7, 1768-1776 (2007).
62. Selkoe DJ. The molecular pathology of Alzheimers disease. Neuron 6(4), 487-498 (1991).
63. Murray IV, Proza JF, Sohrabji F, Lawler JM. Vascular and metabolic dysfunction in Alzheimers disease: a review. Exp. Biol. Med. (Maywood) 236(7), 772-782 (2011).
64. Sims NR. Energy metabolism, oxidative stress and neuronal degeneration in Alzheimers disease. Neurodegeneration 5(4), 435-440 (1996).
65. Grammas P. Neurovascular dysfunction, inflammation and endothelial activation: implications for the pathogenesis of Alzheimers disease. J. Neuroinflammation 8, 26 (2011).
66. Marchesi VT. Alzheimers dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J. 25(1), 5-13 (2011).
67. Atamna H, Frey WH II. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimers disease. Mitochondrion 7(5), 297-310 (2007).
68. Parnetti L, Gaiti A, Brunetti M et al. Increased CSF pyruvate levels as a marker of impaired energy metabolism in Alzheimers disease. J. Am. Geriatr. Soc. 43(3), 316-318 (1995).
69. Araujo DM, Lapchak PA, Robitaille Y, Gauthier S, Quirion R. Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimers disease. J. Neurochem. 50(6), 1914-1923 (1988).
70. Hook VY, Kindy M, Reinheckel T, Peters C, Hook G. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem. Biophys. Res. Commun. 386(2), 284-288 (2009).
71. Sutherland RJ, Whishaw IQ, Regehr JC. Cholinergic receptor blockade impairs spatial localization by use of distal cues in the rat. J. Comp. Physiol. Psychol. 96(4), 563-573 (1982).
72. Armstrong RA. The pathogenesis of Alzheimers disease: a reevaluation of the 'amyloid cascade hypothesis'. Int. J. Alzheimers Dis. 2011, 630865 (2011).
73. Saxena U. Alzheimers disease amyloid hypothesis at crossroads: where do we go from here? Expert Opin. Ther. Targets 14(12), 1273-1277 (2010).
74. Gandy S. Testing the amyloid hypothesis of Alzheimers disease in vivo. Lancet Neurol. 9(4), 333-335 (2010).
75. Khachaturian ZS. Revised criteria for diagnosis of Alzheimers disease: National Institute on Aging-Alzheimers Association diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 7(3), 253-256 (2011).
76. Padovani A, Gilberti N, Borroni B. The usefulness of biological and neuroimaging markers for the diagnosis of early-onset Alzheimers disease. Int. J. Alzheimers Dis. 2011, 296374 (2011).
77. Craig-Schapiro R, Kuhn M, Xiong C et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimers disease diagnosis and prognosis. PLoS One 6(4), e18850 (2011).
78. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimers disease: recommendations from the National Institute on Aging- Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 7(3), 263-269 (2011).
79. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimers disease: recommendations from the National Institute on Aging-Alzheimers Association workgroups on diagnostic guidelines for Alzheimers disease. Alzheimers Dement. 7(3), 270-279 (2011).
80. Vann AS. Ten things you should do when the diagnosis is Alzheimers. Am. J. Alzheimers Dis. Other Demen. 26(2), 93-96 (2011).
81. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 26(Suppl. 1), S1-S58 (2011).
82. Hickey P, Stacy M. Available and emerging treatments for Parkinson's disease: a review. Drug Des. Devel. Ther. 5, 241-254 (2011).
83. Lapchak PA, Gash DM, Jiao S, Miller PJ, Hilt D. Glial cell line-derived neurotrophic factor: a novel therapeutic approach to treat motor dysfunction in Parkinson's disease. Exp. Neurol. 144(1), 29-34 (1997).
84. Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 20(6), 477-505 (2006).
85. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J. Neurol. 244(1), 2-8 (1997).
86. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 106(Pt 2), 257-270 (1983).
87. Beal MF. Therapeutic approaches to mitochondrial dysfunction in Parkinson's disease. Parkinsonism Relat. Disord. 15(Suppl. 3), S189-S194 (2009).
88. Lin TK, Liou CW, Chen SD et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease. Chang Gung Med. J. 32(6), 589-599 (2009).
89. Winklhofer KF, Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochim. Biophys. Acta 1802(1), 29-44 (2010).
90. Park J, Kim Y, Chung J. Mitochondrial dysfunction and Parkinson's disease genes: insights from Drosophila. Dis. Model Mech. 2(7-8), 336-340 (2009).
91. Malkus KA, Tsika E, Ischiropoulos H. Oxidative modifications, mitochondrial dysfunction, and impaired protein degradation in Parkinson's disease: how neurons are lost in the Bermuda triangle. Mol. Neurodegener. 4, 24 (2009).
92. Banerjee R, Starkov AA, Beal MF, Thomas B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta 1792(7), 651-663 (2009).
93. Trimmer PA, Schwartz KM, Borland MK, De Taboada L, Streeter J, Oron U. Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy. Mol. Neurodegener. 4, 26 (2009).
94. Shaw VE, Spana S, Ashkan K et al. Neuroprotection of midbrain dopaminergic cells in MPTP-treated mice after near-infrared light treatment. J. Comp. Neurol. 518(1), 25-40 (2010).
95. Komel'kova LV, Vitreshchak TV, Zhirnova IG et al. [Biochemical and immunological induces of the blood in Parkinson's disease and their correction with the help of laser therapy]. Patol. Fiziol. Eksp. Ter. (1), 15-18 (2004).
96. Lapchak PA, Wu Q. Vascular dysfunction in brain hemorrhage: translational pathways to developing new treatments from old targets. J. Neurol. Neurophysiol. doi:10.4172/2155-9562.S4171-e4001 (2011) (Epub ahead of print).
97. Lapchak PA, Han MK, Salgado KF, Streeter J, Zivin JA. Safety profile of transcranial near-infrared laser therapy administered in combination with thrombolytic therapy to embolized rabbits. Stroke 39(11), 3073-3078 (2008).
98. Ham WT Jr, Clarke AM, Geeraets WJ, Cleary SF, Mueller HA, Williams RC. The eye problem in laser safety. Arch. Environ. Health. 20(2), 156-160 (1970).
99. Denton ML, Foltz MS, Schuster KJ, Estlack LE, Thomas RJ. Damage thresholds for cultured retinal pigment epithelial cells exposed to lasers at 532 nm and 458 nm. J. Biomed. Opt. 12(3), 034030 (2007).
100. Denton ML, Foltz MS, Estlack LE et al. Damage thresholds for exposure to NIR and blue lasers in an in vitro RPE cell system. Invest. Ophthalmol. Vis. Sci. 47(7), 3065-3073 (2006)